Suven Life Sciences is participating and presenting positive Pre-clinical and Phase-1 clinical data of several advanced molecules from their portfolio of new chemical entities (NCEs) and the status of Phase 2 clinical trial of their lead compound SUVN-502 at Neuroscience 2017, organized by Society for Neuroscience being held at Washington DC, USA during 13-15 November 2017. These data presentations highlight Suven’s continued commitment to explore new treatment options addressing unmet medical need through novel mechanisms and targets.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.
